D
Dong Wan Kim
Researcher at Seoul National University Hospital
Publications - 880
Citations - 61091
Dong Wan Kim is an academic researcher from Seoul National University Hospital. The author has contributed to research in topics: Lung cancer & Crizotinib. The author has an hindex of 89, co-authored 833 publications receiving 49632 citations. Previous affiliations of Dong Wan Kim include University of California, Irvine & Korea University.
Papers
More filters
Journal ArticleDOI
Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial.
Daniel Shao-Weng Tan,Alice T. Shaw,Ranee Mehra,Enriqueta Felip,Laura Q.M. Chow,D. Ross Camidge,Johan Vansteenkiste,Sunil Sharma,Tommaso De Pas,Gregory J. Riely,Benjamin Solomon,Juergen Wolf,Michael Thomas,Martin Schuler,Geoffrey Liu,Armando Santoro,Margarida Geraldes,Anthony Boral,A. Yovine,Dong Wan Kim +19 more
TL;DR: A subgroup analysis of the data for pts with ALK+ NSCLC receiving ceritinib at 750 mg/day is reported, as inter-ethnic variations can lead to differences in treatment response in Asian vs Caucasian pts.
Journal ArticleDOI
Colorectal cancer in Korea: characteristics and trends.
TL;DR: The characteristics of Korean colorectal cancer patients were remarkably different from those seen in Western countries in age and primary tumor site distribution, however, the differences were less evident with time.
Journal ArticleDOI
First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).
Vera Hirsh,James Chih-Hsin Yang,Eng Huat Tan,Kenneth J. O'Byrne,Li Zhang,Michael Boyer,Tony Mok,Ki Hyeong Lee,Shun Lu,Yuankai Shi,Sang-We Kim,Janessa Laskin,Dong Wan Kim,Catherine Dubos Arvis,Karl Kölbeck,Martin Schuler,Dan Massey,Angela Maerten,Luis Paz-Ares,Keunchil Park +19 more
TL;DR: The phase IIb LUX-Lung 7 trial compared the 2nd-generation ErbB family blocker, A 40mg/day, and the 1st-generation reversible EGFR TKI, G 250 mg/day in pts with treatment with treatment (tx...
Journal ArticleDOI
Comparison of subchronic immunotoxicity of four different types of aluminum-based nanoparticles.
Eun Jung Park,Sang-Jin Lee,Gwang Hee Lee,Dong Wan Kim,Cheolho Yoon,Byoung Seok Lee,Younghun Kim,Jaerak Chang,Kyuhong Lee +8 more
TL;DR: It is found that the pulmonary biopersistence of Al‐NPs was strengthened by a high aspect ratio in the rod‐ type AlONPs and by the presence of hydroxyl groups in the spherical‐type Al‐nPs, while the commercially available AlCeONPs were Al2O3‐coated CeO2 NPs, but not AlCCeO3 Nps, although they have been sold under the trade name of AlCEONPs.
Journal ArticleDOI
A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).
Hye Ryun Kim,Joung Soon Jang,Jong Mu Sun,Myung-Ju Ahn,Dong Wan Kim,Inkyung Jung,Ki Hyeong Lee,Joo Hang Kim,Dae Ho Lee,Sang We Kim,Byoung Chul Cho +10 more
TL;DR: The dual inhibition of EGFR with nimotuzumab plus gefitinib was not associated with better outcomes than gefithinib alone as a second-line treatment of advanced NSCLC and combined treatment did not increase EGFR inhibition-related adverse events with manageable toxicities.